Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Valley Research-Trials

Neither a doctor nor a teaching hospital

Research payments

$1,870,472

70 payments

Through program year 2025, Valley Research-Trials is reported as receiving $1,870,472 in research payments, across 70 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $2,196 1
2024 Research $285,724 15
2023 Research $549,548 14
2022 Research $195,131 9
2021 Research $157,308 9
2020 Research $374,389 12
2019 Research $306,177 10

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,860,358 69 payments
  2. Lexicon Pharmaceuticals, Inc. $10,114 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Randomized, Phase 3, Double-Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With Or Without Metformin $476,203 5 payments
  2. A Phase 3 Multicenter Randomized Parallel-Design Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $257,446 2 payments
  3. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $166,389 3 payments
  4. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized Double-Blind Placebo-Controlled Trial (Triumph-1) $162,882 2 payments
  5. A Phase 2 Study of Once-Weekly Ly3437943 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $130,271 3 payments
  6. A Phase 2 Study of Once-Weekly Ly3437943 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $127,612 1 payment
  7. A Randomized, Phase 3, Open-Label Trial Comparing the Effect of Ly3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes $125,165 4 payments
  8. A Phase 3 Parallel-Design Open-Label Randomized Control Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared to Insulin Degludec in Insulin Naive Adults With Type 2 Diabetes $93,921 3 payments
  9. A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Study to Evaluate the Efficacy and Safety of Ly3209590 As A Weekly Basal Insulin Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy $69,326 3 payments
  10. A Prospective, Randomized, Double-Blind Comparison of Ly900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion $62,864 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record